The American Society for Pharmacy Law (ASPL) is an organization of attorneys, pharmacists, pharmacist-attorneys and students of pharmacy or law who are interested in the law as it applies to pharmacy, pharmacists, wholesalers, manufacturers, state and federal government and other interested parties.

ASPL is a non-profit which encourages diversity & inclusion with the Society, regardless of differing backgrounds, perspectives, experiences, orientations, origins, and practice settings. The Society embraces participation and diversity as it leads to advancing our purpose: 

  • Furthering knowledge in the law related to pharmacists, pharmacies, the provision of pharmaceutical care, the manufacturing and distribution of drugs, and other food, drug, and medical device policy issues;
  • Communicating accurate legal educational information; and
  • Providing educational opportunities for pharmacists, attorneys, and others who are interested in pharmacy law

Latest News

CMS Releases List of 15 Drugs for MDPNP Effective 2028

The Centers for Medicare & Medicaid Services (CMS) announced the selection of 15 high-cost prescription drugs covered under Medicare Part D and, for the first time, drugs payable under Medicare Part B for the third cycle of the Medicare Drug Price Negotiation Program (MDPNP). CMS also selected one previously negotiated drug for the program’s first renegotiations. Negotiations with participating drug companies will occur in 2026 and any negotiated and renegotiated prices will become effective January 1, 2028. 

The selected drug list for the third cycle of negotiations is: Anoro Ellipta; Biktarvy; Botox/Botox Cosmetic; Cimzia; Cosentyx; Entyvio; Erleada; Kisqali; Lenvima; Orencia; Rexulti; Trulicity; Verzenio; Xeljanz/Xeljanz XR; and Xolair. The selected drug for renegotiation is Tradjenta. See here for a fact sheet on the drugs selected for negotiation and renegotiation.

CMS has also released a list of 50 top negotiation-eligible drugs based on combined expenditures under Medicare Parts B and D. The drugs selected for the third cycle represent the top 15 highest-spending drugs on this list.